ArticleJGH open : an open access journal of gastroenterology and hepatology2020
A retrospective analysis of hyponatremia during terlipressin treatment in patients with esophageal or gastric variceal bleeding due to portal hypertension.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Real-world safety of terlipressin in elderly patients with liver cirrhosis and esophagogastric variceal bleeding: a focus on hyponatremia and administration methods.Frontiers in pharmacology · 2026Article
- Beyond conventional treatments: cutting-edge strategies for ascites in cirrhosis.Frontiers in medicine · 2026Review
- Hyponatraemia Induced by Terlipressin in Patients Diagnosed with Decompensated Liver Cirrhosis and Acute Variceal Bleeding.Medicines (Basel, Switzerland) · 2025Article
- Terlipressin-Induced Hyponatremic Seizures in a Patient With Congenital Hepatic Fibrosis.HCA healthcare journal of medicine · 2025Article
- Article
- Evidence-based hyponatremia management in liver disease.Clinical and molecular hepatology · 2023Review
- Hyponatremia in Cirrhosis.Clinics in liver disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTo explore the risk factors of hyponatremia caused by terlipressin.
methodsForty-four patients with acute variceal bleeding treated with terlipressin from December 2016 to December 2018 were analyzed.
resultsDuring the treatment, serum sodium levels decreased from 137.78 to 126.59 mmol/L (
conclusionThe incidence of hyponatremia is not low during treatment with terlipressin; a higher baseline serum sodium level is a risk factor for hyponatremia during treatment with terlipressin, and the mechanism may be related to endogenous vasopressin preconditioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.